Wu Bin, Wang Jing, Wang Xiaoguang, Zhu Mingyuan, Chen Fei, Shen Yiyu, Zhong Zhengxiang
Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang 314000, P.R. China.
Oncol Lett. 2020 Nov;20(5):257. doi: 10.3892/ol.2020.12120. Epub 2020 Sep 18.
Immunotherapy based on the tumor microenvironment is a feasible method for treating cancer; therefore, it is necessary to investigate the immune microenvironment of pancreatic cancer and the influencing factors of the immune microenvironment. Chemokines are an important factor affecting the tumor immune microenvironment. In the present study, chemokines or chemokine receptors were screened to identify those differentially expressed in pancreatic cancer compared with normal controls and associated with patient prognosis. Chemokines or chemokine receptors that are differentially expressed in pancreatic cancer tumor tissues were initially screened using the Gene Expression Omnibus database. Next, survival analysis was performed using GEPIA, a website based on The Cancer Genome Atlas (TCGA) database. Immunohistochemical staining of CXCL5 was performed in tissue microarrays (TMAs) containing 119 cases of pancreatic cancer. Histochemistry score (H-SCORE) was used to evaluate the expression of CXCL5. Next, association analysis of the H-SCORE of CXCL5 and the clinical characteristics of patients was performed, as well as Kaplan-Meier survival and Cox multivariate regression analyses. The results of the bioinformatics analysis demonstrated that CXCL5 was highly expressed in pancreatic cancer tissues. High expression of CXCL5 in pancreatic cancer tissues was associated with a poor prognosis in patients in TCGA cohort. The expression level of CXCL5 in tumor tissues was significantly higher compared with that in adjacent peritumoral normal tissues in the immunohistochemical analysis. There was no significant association between CXCL5 expression in pancreatic cancer tumor tissues and clinicopathological factors. Patients with pancreatic cancer with high CXCL5 expression had a poor prognosis, as determined by Kaplan-Meier survival analysis based on the TMA dataset. The results of Cox multivariate regression analysis showed that CXCL5 was an independent factor for a poor prognosis in patients with pancreatic cancer. In conclusion, the results of the present study revealed that the chemokine CXCL5 was highly expressed in pancreatic cancer tissues; high CXCL5 expression was associated with a poor prognosis in patients with pancreatic cancer.
基于肿瘤微环境的免疫疗法是治疗癌症的一种可行方法；因此，有必要研究胰腺癌的免疫微环境以及免疫微环境的影响因素。趋化因子是影响肿瘤免疫微环境的重要因素。在本研究中，筛选趋化因子或趋化因子受体，以鉴定与正常对照相比在胰腺癌中差异表达且与患者预后相关的因子。首先使用基因表达综合数据库筛选在胰腺癌肿瘤组织中差异表达的趋化因子或趋化因子受体。接下来，使用基于癌症基因组图谱（TCGA）数据库的网站GEPIA进行生存分析。在包含119例胰腺癌的组织微阵列（TMA）中进行CXCL5的免疫组织化学染色。使用组织化学评分（H-SCORE）评估CXCL5的表达。接下来，进行CXCL5的H-SCORE与患者临床特征的关联分析，以及Kaplan-Meier生存分析和Cox多因素回归分析。生物信息学分析结果表明，CXCL5在胰腺癌组织中高表达。在TCGA队列中，胰腺癌组织中CXCL5的高表达与患者预后不良相关。免疫组织化学分析显示，肿瘤组织中CXCL5的表达水平明显高于相邻的瘤旁正常组织。胰腺癌肿瘤组织中CXCL5的表达与临床病理因素之间无显著关联。基于TMA数据集的Kaplan-Meier生存分析表明，CXCL5高表达的胰腺癌患者预后不良。Cox多因素回归分析结果显示，CXCL5是胰腺癌患者预后不良独立因素。总之，本研究结果表明，趋化因子CXCL5在胰腺癌组织中高表达；CXCL5高表达与胰腺癌患者预后不良相关。
